|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RPL26 |
Gene summary for RPL26 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RPL26 | Gene ID | 6154 |
| Gene name | ribosomal protein L26 | |
| Gene Alias | DBA11 | |
| Cytomap | 17p13.1 | |
| Gene Type | protein-coding | GO ID | GO:0000075 | UniProtAcc | P61254 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6154 | RPL26 | SYSMH4 | Human | Oral cavity | OSCC | 1.59e-119 | 2.96e+00 | 0.1226 |
| 6154 | RPL26 | SYSMH5 | Human | Oral cavity | OSCC | 6.26e-24 | 1.35e+00 | 0.0647 |
| 6154 | RPL26 | SYSMH6 | Human | Oral cavity | OSCC | 1.39e-22 | 3.43e+00 | 0.1275 |
| 6154 | RPL26 | HTA12-23-1 | Human | Pancreas | PDAC | 2.56e-14 | -1.56e+00 | 0.3405 |
| 6154 | RPL26 | HTA12-25-1 | Human | Pancreas | PDAC | 4.17e-17 | -1.45e+00 | 0.313 |
| 6154 | RPL26 | HTA12-26-1 | Human | Pancreas | PDAC | 8.15e-30 | -1.55e+00 | 0.3728 |
| 6154 | RPL26 | HTA12-29-1 | Human | Pancreas | PDAC | 1.62e-75 | -1.57e+00 | 0.3722 |
| 6154 | RPL26 | HTA12-32-1 | Human | Pancreas | PDAC | 4.00e-04 | -1.60e+00 | 0.3624 |
| 6154 | RPL26 | 3829-EC | Human | Pancreas | PanIN | 2.72e-04 | -3.42e-01 | 0.009 |
| 6154 | RPL26 | 4347-EC | Human | Pancreas | PanIN | 4.01e-11 | -1.83e-01 | 0.0572 |
| 6154 | RPL26 | DS20191261Tumor | Human | Pancreas | PDAC | 4.82e-19 | -9.54e-01 | 0.1367 |
| 6154 | RPL26 | GSM5252126_BPH283PrGF_Via | Human | Prostate | BPH | 1.72e-50 | 2.49e+00 | -0.1771 |
| 6154 | RPL26 | GSM5252127_BPH283PrSF_Via | Human | Prostate | BPH | 3.54e-45 | 2.07e+00 | -0.1453 |
| 6154 | RPL26 | GSM5252128_BPH327PrGF_Via | Human | Prostate | BPH | 1.88e-80 | 2.48e+00 | -0.1688 |
| 6154 | RPL26 | GSM5252129_BPH327PrSF_Via | Human | Prostate | BPH | 4.66e-82 | 2.55e+00 | -0.1697 |
| 6154 | RPL26 | GSM5252130_BPH340PrGF_Via | Human | Prostate | BPH | 1.75e-73 | 2.97e+00 | -0.1972 |
| 6154 | RPL26 | GSM5252131_BPH340PrSF_Via | Human | Prostate | BPH | 5.44e-88 | 3.66e+00 | -0.2126 |
| 6154 | RPL26 | GSM5252132_BPH389PrGF | Human | Prostate | BPH | 4.06e-17 | 3.05e+00 | -0.2247 |
| 6154 | RPL26 | GSM5252133_BPH389PrSF | Human | Prostate | BPH | 1.15e-12 | 3.06e+00 | -0.2027 |
| 6154 | RPL26 | GSM5252134_BPH511PrG_Fcol_3GEX | Human | Prostate | BPH | 1.40e-65 | 2.31e+00 | -0.1433 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00021819 | Breast | Precancer | cytoplasmic translation | 80/1080 | 148/18723 | 1.59e-59 | 8.54e-56 | 80 |
| GO:00226139 | Breast | Precancer | ribonucleoprotein complex biogenesis | 79/1080 | 463/18723 | 2.11e-18 | 1.03e-15 | 79 |
| GO:00971939 | Breast | Precancer | intrinsic apoptotic signaling pathway | 59/1080 | 288/18723 | 8.07e-18 | 3.60e-15 | 59 |
| GO:20012339 | Breast | Precancer | regulation of apoptotic signaling pathway | 65/1080 | 356/18723 | 7.70e-17 | 3.17e-14 | 65 |
| GO:20012429 | Breast | Precancer | regulation of intrinsic apoptotic signaling pathway | 41/1080 | 164/18723 | 6.48e-16 | 2.31e-13 | 41 |
| GO:00422549 | Breast | Precancer | ribosome biogenesis | 52/1080 | 299/18723 | 7.35e-13 | 1.51e-10 | 52 |
| GO:00064179 | Breast | Precancer | regulation of translation | 67/1080 | 468/18723 | 4.71e-12 | 7.64e-10 | 67 |
| GO:00457279 | Breast | Precancer | positive regulation of translation | 32/1080 | 136/18723 | 5.89e-12 | 9.27e-10 | 32 |
| GO:00422739 | Breast | Precancer | ribosomal large subunit biogenesis | 22/1080 | 72/18723 | 5.03e-11 | 5.61e-09 | 22 |
| GO:00342509 | Breast | Precancer | positive regulation of cellular amide metabolic process | 33/1080 | 162/18723 | 1.72e-10 | 1.77e-08 | 33 |
| GO:20012445 | Breast | Precancer | positive regulation of intrinsic apoptotic signaling pathway | 17/1080 | 58/18723 | 1.59e-08 | 1.12e-06 | 17 |
| GO:00063646 | Breast | Precancer | rRNA processing | 35/1080 | 225/18723 | 7.90e-08 | 4.60e-06 | 35 |
| GO:00160726 | Breast | Precancer | rRNA metabolic process | 36/1080 | 236/18723 | 8.59e-08 | 4.84e-06 | 36 |
| GO:20012356 | Breast | Precancer | positive regulation of apoptotic signaling pathway | 24/1080 | 126/18723 | 1.98e-07 | 1.01e-05 | 24 |
| GO:19017989 | Breast | Precancer | positive regulation of signal transduction by p53 class mediator | 10/1080 | 25/18723 | 5.77e-07 | 2.49e-05 | 10 |
| GO:19017969 | Breast | Precancer | regulation of signal transduction by p53 class mediator | 19/1080 | 93/18723 | 1.20e-06 | 4.60e-05 | 19 |
| GO:00723319 | Breast | Precancer | signal transduction by p53 class mediator | 26/1080 | 163/18723 | 2.23e-06 | 7.76e-05 | 26 |
| GO:00723328 | Breast | Precancer | intrinsic apoptotic signaling pathway by p53 class mediator | 16/1080 | 76/18723 | 5.49e-06 | 1.63e-04 | 16 |
| GO:00103323 | Breast | Precancer | response to gamma radiation | 13/1080 | 56/18723 | 1.35e-05 | 3.38e-04 | 13 |
| GO:19022537 | Breast | Precancer | regulation of intrinsic apoptotic signaling pathway by p53 class mediator | 9/1080 | 29/18723 | 2.40e-05 | 5.53e-04 | 9 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0301018 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
| hsa0517118 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
| hsa0301019 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
| hsa0517119 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
| hsa0301024 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
| hsa0517124 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
| hsa0301034 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
| hsa0517134 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
| hsa0301044 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
| hsa0517144 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
| hsa0301054 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
| hsa0517154 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
| hsa0517120 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
| hsa0301020 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
| hsa05171110 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
| hsa03010110 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
| hsa0301025 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
| hsa0517125 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
| hsa0301035 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
| hsa0517135 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
| Page: 1 2 3 4 5 6 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RPL26 | SNV | Missense_Mutation | c.149G>A | p.Arg50Gln | p.R50Q | P61254 | protein_coding | tolerated(0.11) | benign(0.029) | TCGA-A8-A0A7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| RPL26 | SNV | Missense_Mutation | c.377N>A | p.Arg126His | p.R126H | P61254 | protein_coding | tolerated(0.21) | benign(0.001) | TCGA-E2-A1LL-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | docetaxel | PD | |
| RPL26 | SNV | Missense_Mutation | novel | c.175N>G | p.Arg59Gly | p.R59G | P61254 | protein_coding | deleterious(0.02) | benign(0.131) | TCGA-VS-A8QA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| RPL26 | SNV | Missense_Mutation | rs757117420 | c.358N>A | p.Glu120Lys | p.E120K | P61254 | protein_coding | deleterious(0.04) | benign(0.013) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| RPL26 | SNV | Missense_Mutation | c.377G>A | p.Arg126His | p.R126H | P61254 | protein_coding | tolerated(0.21) | benign(0.001) | TCGA-D5-6540-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| RPL26 | SNV | Missense_Mutation | novel | c.344N>A | p.Arg115His | p.R115H | P61254 | protein_coding | tolerated(0.11) | benign(0.003) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| RPL26 | SNV | Missense_Mutation | novel | c.87N>G | p.Ile29Met | p.I29M | P61254 | protein_coding | tolerated(0.06) | benign(0.024) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
| RPL26 | SNV | Missense_Mutation | novel | c.92C>A | p.Ser31Tyr | p.S31Y | P61254 | protein_coding | deleterious(0) | benign(0.289) | TCGA-EO-A3AY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| RPL26 | SNV | Missense_Mutation | novel | c.188A>C | p.Lys63Thr | p.K63T | P61254 | protein_coding | deleterious(0) | possibly_damaging(0.528) | TCGA-EY-A1G8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RPL26 | SNV | Missense_Mutation | c.149N>A | p.Arg50Gln | p.R50Q | P61254 | protein_coding | tolerated(0.11) | benign(0.029) | TCGA-55-6968-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Chemotherapy | unknown | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |